Qiagen NV (QGEN)

27.29
NASDAQ : Services
Prev Close 26.89
Day Low/High 27.10 / 27.60
52 Wk Low/High 19.94 / 28.50
Avg Volume 1.07M
Exchange NASDAQ
Shares Outstanding 234.25M
Market Cap 6.30B
EPS 0.50
P/E Ratio 49.80
Div & Yield N.A. (N.A)

Latest News

QIAGEN Shareholders Approve Return Of Approximately $250 Million In Cash To Shareholders Via Synthetic Share Repurchase

QIAGEN Shareholders Approve Return Of Approximately $250 Million In Cash To Shareholders Via Synthetic Share Repurchase

Adjustment to capital structure through reduction in number of shares outstanding and direct capital repayment to shareholders expected to be completed in January 2017

QIAGEN Launches QIAscout For Single-cell Isolation

QIAGEN Launches QIAscout For Single-cell Isolation

Compact, versatile and yet very affordable instrument provides unique front-end in workflows for molecular analysis of individual cells

What IBM's Genomic Partnership With Quest Says About Thermo Fisher, Diagnostics Peers

What IBM's Genomic Partnership With Quest Says About Thermo Fisher, Diagnostics Peers

Quest and IBM are rolling out a genomic sequencing service powered by Big Blue's Watson supercomputer.

QIAGEN Unveils Unique Sample To Insight Solutions For Liquid Biopsies And Hereditary Diseases

QIAGEN Unveils Unique Sample To Insight Solutions For Liquid Biopsies And Hereditary Diseases

All-in-One library prep kit, plus collection, stabilization and bioinformatics solutions enable NIPT and cancer research

QIAGEN Launches High-throughput Solutions For Human ID Databases

QIAGEN Launches High-throughput Solutions For Human ID Databases

Partnering with Hamilton Robotics to deliver automated workflows for DNA fingerprinting

QIAGEN Announces Plans To Return Approximately $250 Million To Shareholders Via Synthetic Share Repurchase Proposal

QIAGEN Announces Plans To Return Approximately $250 Million To Shareholders Via Synthetic Share Repurchase Proposal

Proposal would adjust capital structure through 4% reduction in number of shares outstanding and direct capital repayment to shareholders

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AEUA, BPMC, CAA, CAT, COMM, DAIO, DKS, EFII, HDS, HOG, ISTR, KEM, MSCC, MT, NWHM, QGEN, QLYS, TPRE Downgrades: COHU, DMD, EMN, GRC, SFS, SYNA, WWE Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

3 Diversified Services Stocks Nudging The Industry Higher

3 Diversified Services Stocks Nudging The Industry Higher

TheStreet highlights 3 stocks pushing the diversified services industry higher today.

Qiagen (QGEN) Stock Soars as Q2 Results Surpass Expectations

Qiagen (QGEN) Stock Soars as Q2 Results Surpass Expectations

Qiagen (QGEN) stock is jumping on Friday morning after the company posted earnings and revenue that topped analysts’ projections for the 2016 second quarter.

Watch Out: Barbarians At The Gate For Qiagen (QGEN)

Watch Out: Barbarians At The Gate For Qiagen (QGEN)

Trade-Ideas LLC identified Qiagen (QGEN) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

QIAGEN Launches

QIAGEN Launches "Digital NGS" Solutions With Unique Molecular Index Technology To Reliably Detect All Genetic Variation

QIAseq Targeted NGS panels deliver highly sensitive, unbiased and accurate NGS insights

Buy These 5 Stocks This Week for Breakout Gains

Buy These 5 Stocks This Week for Breakout Gains

These five technical setups are showing solid upside potential right now.

QIAGEN Announces Successful Completion Of Tender Offer For Shares In Exiqon

QIAGEN Announces Successful Completion Of Tender Offer For Shares In Exiqon

Transaction will enhance leadership position in RNA solutions from Sample to Insight

21 Buzzwords That Goldman Sachs Thinks All Investors Should Know Now

21 Buzzwords That Goldman Sachs Thinks All Investors Should Know Now

Ever hear of space congestion, Bots or liquid biopsy? The phrases are part of a group of 21 investment buzzwords identified by Goldman Sachs in its annual buzzword report.

QIAGEN Joins Consortium To Map Microbial Genomes In 54 Cities

QIAGEN Joins Consortium To Map Microbial Genomes In 54 Cities

Project that measured pathogens in New York City subways goes global this summer

QIAGEN Launches QIAsure Methylation Test To Determine Cervical Cancer Risk

QIAGEN Launches QIAsure Methylation Test To Determine Cervical Cancer Risk

New follow-up assay helps stratify patients with transforming HPV infections

QIAGEN Changes Offer Conditions For Acquisition Of Shares In Exiqon A/S

QIAGEN Changes Offer Conditions For Acquisition Of Shares In Exiqon A/S

Acceptance rate lowered to 89.20% of share capital and voting rights to reflect possible effect of warrants

QIAGEN Announces Second Offer Extension For The Acquisition Of Shares In Exiqon A/S

QIAGEN Announces Second Offer Extension For The Acquisition Of Shares In Exiqon A/S

Offer for DKK 18 per share remains valid until 20 June 2016

QIAGEN Forms Lung Cancer Expert Alliance

QIAGEN Forms Lung Cancer Expert Alliance

Key opinion leaders' expertise to guide design of new gene panels for GeneReader NGS

QIAGEN Launches Liquid Biopsy Workflow For GeneReader NGS System

QIAGEN Launches Liquid Biopsy Workflow For GeneReader NGS System

Actionable Insights Tumor Panel enables monitoring of cancer biomarkers from plasma samples

QIAGEN Integrates Quality Control Tools Into GeneReader NGS System

QIAGEN Integrates Quality Control Tools Into GeneReader NGS System

Reference data set from Horizon affirms proven accuracy of GeneReader workflow